XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Net sales $ 715,931 $ 536,880 $ 1,442,727 $ 1,108,524
Cost of goods sold 314,333 243,892 640,502 498,168
Gross profit 401,598 292,988 802,225 610,356
Selling, general and administrative expense 213,425 189,262 439,278 382,954
Research and Development Expense 63,391 51,984 137,303 101,287
Segment profit (loss) 124,782 51,742 225,644 126,115
Interest expense 363 5,740 761 11,430
Foreign exchange (gains) losses, net (1,761) 774 (1,690) 1,702
Marketable Securities, Unrealized (Gain) Loss (1,030,691) (1,183,488) (2,210,094) (2,011,159)
Other Nonoperating Income (Expense) (96) 17,229 17,311 20,502
Income before income taxes 1,156,775 1,245,945 2,453,978 2,144,644
(Provision) benefit for income taxes (242,661) (279,516) (562,450) (492,303)
Net income attributable to Bio-Rad $ 914,114 $ 966,429 $ 1,891,528 $ 1,652,341
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 30.71 $ 32.59 $ 63.49 $ 55.52
Weighted average common shares - basic 29,764 29,652 29,793 29,759
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 30.32 $ 32.15 $ 62.70 $ 54.84
Weighted average common shares - diluted 30,148 30,058 30,167 30,131